Eligibility: The deciding factor. Eligibility Criteria Select subjects that are as homogenous as possible Select subjects that are as homogenous as possible.

Slides:



Advertisements
Similar presentations
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
Advertisements

The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
Adverse Events and Serious Adverse Events
Protocol Deviations : Identification, Responses and Solutions The Office of Human Subjects Research’s Compliance Monitoring Program Educational Seminars:
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.
1st Global QA Conference & 21st SQA Annual Meeting Falcon Consulting Group, LLC 1 Phase I Clinical Study Audits “A Deeper Scrutiny” Cheryl J. Priest, R.N.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
1 © Huron Consulting Group Inc. All rights reserved. Huron is a management consulting firm and not a CPA firm, and does not provide attest services, audits,
ROLE OF NURSES IN CLINICAL RESEARCH IN MALAWI OWEN DAIRE BSCN MPH RNM.
Pharmacists Responsibilities in Clinical Studies Mike R Sather, PhD Crystal L Harris, PharmD February 26, 2004.
John Naim, PhD Director Clinical Trials Research Unit
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Identification & Distinction of Clinical Trial Participant Charges Bethany Martell Office of Clinical Research Associate Director- Financial Operations.
8 Criteria for IRB Approval of Research 45 CFR (a)
Tipologie di Audit e loro caratteristiche Riunione sottogruppo GCP-GIQAR 21 Marzo 2006 Francesca Bucchi.
Clinical Trials The Way We Make Progress Against Disease.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Accredited Member of the Association of Clinical Research Professionals, USA Tips on clinical trials Maha Al-Farhan B.Sc, M.Phil., M.B.A., D.I.C.
Internal Auditing in Research: The QA Process Research Education Series February 14, 2011 Sarah Dutkevitch, RN, OCN, Clinical Research Nurse Specialist.
CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
Planned Emergency Research Exception from Informed Consent Requirements September 2007.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
TERRENCE F. ACKERMAN, PH.D. PROFESSOR OF BIOETHICS CHAIR, UTHSC IRB.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Consent for Research Study A study for patients newly diagnosed with advanced glioblastoma (brain cancer): Learning whether a PET scan with F-fluoromisonidazole.
Conducting Surveys Presented by: Kay Lam Gallaudet Research Institute address:
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
CTMB Guidelines (Rev. October 2006) Section 5: Conducting the Quality Assurance Audit.
1 Auditing and Monitoring Gerald Beccia/RCO VA CT Healthcare System.
Office of Human Research Protection Georgia Health Sciences University.
Conducting Research at Lincoln IRB/HRPP Policies, Procedures & Good Clinical Practices B Kanna MD, MPH, FACP Associate Program Director of Internal Medicine.
Sponsor Visits and Monitoring
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
Responsibilities of Sponsor, Investigator and Monitor
Cancer Clinical Trials Office Clinical Trials & Research Training Oct2014.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Good Clinical Practice (GCP) and Monitoring Practices
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
The Role and Responsibilities of the Clinical Research Coordinator
Responsibilities of Sponsor, Investigator and Monitor
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
Basics of Building and Understanding Data Collection Forms
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Quality Control SOP 3.12 Release Date: 08/10/2015.
Protocol Approval Criteria
Good clinical practice
Presentation transcript:

Eligibility: The deciding factor

Eligibility Criteria Select subjects that are as homogenous as possible Select subjects that are as homogenous as possible Control and build variables into the design of the study Control and build variables into the design of the study Answer the trials hypothesis and meet written objectives Answer the trials hypothesis and meet written objectives Patient safety Patient safety

Eligibility Criteria The Good, The Bad and The Ugly Writing eligibility criteria is an art: Must not be overly restrictive Must not be overly restrictive Must not be overly vague Must not be overly vague Must be verifiable Must be verifiable Must be based on “reasonable” practice parameters Must be based on “reasonable” practice parameters Must not be excessive in number Must not be excessive in number

Eligibility Criteria The Good, The Bad and The Ugly Overly Restrictive: Must be 18 years of age Must be 18 years of age HIV test within 14 days of study entry HIV test within 14 days of study entry

Eligibility Criteria The Good, The Bad and The Ugly Overly Vague: Patients on anticoagulation therapy are allowed to have an appropriately prolonged International Normalized Ratio (INR) Patients on anticoagulation therapy are allowed to have an appropriately prolonged International Normalized Ratio (INR)

Eligibility Criteria The Good, The Bad and The Ugly Difficult to verify: THE GOLDEN RULE If the investigator feels that it is important enough to list it as a stand-alone criterion, an audit should feel that it is important enough to source verify If the investigator feels that it is important enough to list it as a stand-alone criterion, an audit should feel that it is important enough to source verify

Eligibility Criteria The Good, The Bad and The Ugly Difficult to verify: History of XXX lesion with large necrotic areas, as determined by the Principal Investigator History of XXX lesion with large necrotic areas, as determined by the Principal Investigator Life expectancy of >12 weeks Life expectancy of >12 weeks

Eligibility Criteria The Good, The Bad and The Ugly Reasonable practice parameters: Patient must be willing to stay within 5 miles of the hospital and return daily for labs. Patient must be willing to stay within 5 miles of the hospital and return daily for labs.

Eligibility Criteria The Good, The Bad and The Ugly Excessive number: Average number of eligibility criteria per protocol is 28 Average number of eligibility criteria per protocol is 28

Source Document: In a clinical trial, source documents are the hard copies on which clinical observations are first recorded. They are legally valid raw data that support a study’s findings. In a clinical trial, source documents are the hard copies on which clinical observations are first recorded. They are legally valid raw data that support a study’s findings.

What Source Documents Do We Look for When Assessing Eligibility? Histology: Histology: CT/CXR, MRI, PET scans: CT/CXR, MRI, PET scans: Labs: Labs:

What Source Documents Do We Look for When Assessing Eligibility? For compound criteria: Histologically or cytologically documented adenocarcinoma of the pancreas not amenable to surgical resection: Histologically or cytologically documented adenocarcinoma of the pancreas not amenable to surgical resection:

What Source Documents Do We Look for When Assessing Eligibility? For the “vague-ities”: Patients have recovered from any surgical procedure Patients have recovered from any surgical procedure

What Parameters Do We Look for When Assessing Eligibility? Did all testing meet the assigned value/intent of the criteria? (CT measurements, labs) Did all testing meet the assigned value/intent of the criteria? (CT measurements, labs) Did on-study note clearly address each “non- measurable” criteria? (date since last chemo, PS, con meds, etc). Did on-study note clearly address each “non- measurable” criteria? (date since last chemo, PS, con meds, etc). If patient did not meet criteria was wiaver appropriately used ? (NCI) If patient did not meet criteria was wiaver appropriately used ? (NCI)

AUDITING HINTS Eligibility criteria are critical; take them seriously Eligibility criteria are critical; take them seriously Read the protocol, know the criteria Read the protocol, know the criteria Develop a tool to capture components Develop a tool to capture components --Study calendar (when things should occur) --Table --Excel spreadsheet Calendar for time patient is on trial (when things actually occur) Calendar for time patient is on trial (when things actually occur) Review how research nurse captures data and sets up research files Review how research nurse captures data and sets up research files Create uninterrupted time Create uninterrupted time

DEAL or NO DEAL ? YOU DECIDE

Criteria: Ambulatory, medically stable persons; community dwelling; able to give informed consent and available for all study visits; able to understand and comply with planned study procedures; ECOG performance status < 2. Ambulatory, medically stable persons; community dwelling; able to give informed consent and available for all study visits; able to understand and comply with planned study procedures; ECOG performance status < 2.

Criteria: Patients may have received one systemic chemotherapy regimen for XXXX tumor. There is no limit to the number of biological or immunotherapeutic regimens received by patients. Patients may have received one systemic chemotherapy regimen for XXXX tumor. There is no limit to the number of biological or immunotherapeutic regimens received by patients.

Criteria: Total bilirubin is less than or equal to 1.5 times the institutional upper limit of normal, SGOT less than or equal to 1.5 times the institutional upper limit of normal.

Criteria Patients with active infection Patients with active infection

Criteria: History of psychiatric illness/social situation that would limit compliance with study requirements History of psychiatric illness/social situation that would limit compliance with study requirements

POINTS TO REMEMBER Your role as an auditor is to: Verify that the investigator is enrolling only eligible subjects [GCP (i)] Verify that the investigator is enrolling only eligible subjects [GCP (i)] Protect the rights/well-being of human subjects Protect the rights/well-being of human subjects Ensure the integrity of the data Ensure the integrity of the data Verify that the conduct of the protocol is consistent with the IRB approved protocol, all federal and state regulations, GCP guidelines and institutional policy. Verify that the conduct of the protocol is consistent with the IRB approved protocol, all federal and state regulations, GCP guidelines and institutional policy. Not stated = not verified Questionable data = unacceptable loss

PRACTICE TIME